EMA发布国际原料药检查项目2017至2024年报告(EMA/202541/2026)
Report on the International Active Pharmaceutical Ingredient Inspection Programme 2017 – 2024
EMA发布国际原料药检查项目2017至2024年报告(EMA/202541/2026),参与机构由10个增至13个,期间共共享936个场址、1684次检查的信息。644个场址(69%)被两家及以上机构共同关注,107个场址采用检查依赖,联合检查27次、占共同关注场址的4.2%。报告还记录91次远程检查,并提出改善信息共享与减少重复检查的后续行动建议。
汇总2017至2024年国际原料药检查项目的参与机构、检查量与检查依赖数据,可与上一期报告对照。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
7 September 2026
European Medicines Agency
EMA/202541/2026
Report on the International Active Pharmaceutical
Ingredient Inspection Programme 2017 – 2024
Table of Contents
1. Executive summary .................................................................. 2
2. Objective of this report ............................................................ 3
3. Goals of the initiative ............................................................... 3
4. History and membership .......................................................... 4
5. Tools of the programme ........................................................... 5
5.1. Master List and other platforms for exchange .......................... 5
5.2. Non-compliance Alerting and Regulatory action ....................... 5
5.3. Secretariat of the group, monthly meetings, bi/multilateral
meetings ........................................................................................... 6
6. Deliverables ............................................................................. 7
6.1. Number of sites inspected and number of inspections ............. 7
6.2. Sites of shared interest ............................................................ 8
6.3. Multiple (duplicates) inspections ............................................. 9
6.4. Remote inspections ................................................................ 11
6.5. Joint inspections .................................................................... 12
6.6. Sharing reports and using reliance for the supervision of sites12
6.7. Sustained engagement of participating authorities ................ 14
7. Achievement of the recommendations from the previous
report…………. ................................................................................. 14
8. Recommendations for future action and path forward ........... 15
9. Conclusion .............................................................................. 16
10. References ............................................................................. 17
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.
第 2 页
1. Executive summary
The International Active Pharmaceutical Ingredient (API) Inspection
Programme aims to strengthen global collaboration and information sharing
on Good Manufacturing Practice (GMP) inspections of API manufacturers. By
promoting reliance and reducing duplication, the programme seeks to
optimize inspection resources and enhances regulatory oversight across
participating authorities.
This report covers the period from 2017 to 2024, during which the
programme expanded from 10 to 13 authorities, including Health Canada,
PMDA Japan, and ANVISA Brazil. The COVID-19 pandemic significantly
disrupted on-site inspections activities but also accelerated the adoption of
remote inspections and reinforced reliance-based approaches.
Key achievements include:
• Inspection Activity: information shared regarding 936 sites
inspected, with total inspections increasing by ~50% compared to the
previous period.
• Collaboration and reliance: a high level of convergence was
observed, with 69% of sites identified as being of shared interest
among participating authorities; 107 sites benefited from inspection
reliance.
• Innovation: Remote inspections were introduced (91 conducted).
Key challenges remain:
• Joint inspections decreased, representing only 4.2% of sites of shared
interest, reflecting operational and resource constraints.
• Duplication of inspections persists, particularly for sites with non-
compliance outcomes.
• Legal, confidentiality, and language barriers continue to limit the
effective sharing and use of inspection reports.
• Progress in establishing a centralised data-sharing platform has been
limited due to technical and regulatory constraints.
Overall, the programme has demonstrated clear benefits in improving
information sharing and enabling reliance practices, contributing to more
efficient use of regulatory resources, reduced burden on stakeholders, and
improved environmental sustainability. However, further efforts are required
to address structural and operational barriers.
Moving forward, priorities include:
• Enhancing active participation and ensuring timely information
exchange among authorities.
EMA/202541/2026 Page 2/17
第 3 页
• Improving the usability and accessibility of inspection reports to
facilitate reliance.
• Expanding the use of reliance practices to reduce duplication of
inspections.
• Developing practical guidance and training to support joint inspections.
• Establishing a secure and centralised repository for inspection data and
reports.
2. Objective of this report
The objective of this report is to provide an overview of the functioning and
outputs of the International API Inspection Programme for the period
between 2017 and 2024. The extended review period covered, reflects the
impact of the COVID-19 pandemic, which significantly reduced inspection
activities.
The report assesses the extent to which recommendations from the previous
reporting period have been implemented, reviews key deliverables and
performance indicators, and identifies areas for further improvement, based
on the findings. It also proposes future directions for the programme’s
objectives and operations.
3. Goals of the initiative
The International Active Pharmaceutical Ingredient (API) Inspection
Programme was established in 2008, first as a pilot in late 2008 to late 2010,
and as a full programme since January 2011 with the aim to strengthen
global collaboration and information sharing on Good Manufacturing Practice
(GMP) inspections of API manufacturers, to reduce duplication and to
optimise inspection resources.
Participating authorities agreed that, for sites of common interest, they
would:
• Consider inspections conducted or planned by other authorities when
scheduling or prioritising their own inspection.
• Request, where appropriate, that other authorities expand the scope of
a planned inspection to cover their areas of interest instead of
conducting separate inspections
• Conduct joint inspections with one or more participating authorities
Activity reports were issued at the end of the pilot phase and the period
2011-2016. These reports recommended regular assessment of the
programme and, where necessary, revision of the Terms of Reference. They
also identified remaining challenges, including the need for more active
EMA/202541/2026 Page 3/17
第 4 页
participation by all members and the establishment of a formal electronic
information-sharing platform.
4. History and membership
The International API Inspection Programme comprises 13 participating
authorities, including 10 national authorities and 3 transnational
organisations. The programme was initially established in 2008 with a core
group of authorities, with additional members joining over time as outlined
below.
Founding members (since 2008):
• Australia (Therapeutic Goods Administration/TGA)
• France (Agence Nationale de Sécurité du Médicament et des Produits
de Santé/ANSM)
• Italy (Agenzia Italiana del Farmaco/AIFA)
• Ireland (Health Products Regulatory Authority/HPRA)
• United Kingdom (Medicines and Healthcare products Regulatory
Agency/MHRA)
• Council of Europe, European Directorate for the Quality of Medicines
and Healthcare/EDQM
• European Union, European Medicines Agency/EMA
• United States of America Food and Drug Administration (US FDA)
• Germany - Zentralstelle der Länder für Gesundheitsschutz bei
Arzneimitteln und Medizinprodukten (ZLG), till the end of the pilot
programme
Subsequent members
• Denmark - Danish Medicines Agency (DKMA), since 2011
• World Health Organization (WHO), since 2017 but provided data since
their observership in 2012 and was therefore counted as a member in
the metrics of the previous report
• Canada - Health Canada (HC), since the end of 2016, therefore fully
effective in 2017
• Japan - Pharmaceuticals and Medical Devices Agency (PMDA) Japan,
since the end of 2016, therefore fully effective in 2017
• Brazil - Agência Nacional de Vigilância Sanitária (ANVISA), since 2021.
EMA/202541/2026 Page 4/17
第 5 页
5. Tools of the programme
The programme relies primarily on the Master List, complemented by
additional platforms and mechanisms for information exchange among
participating authorities.
5.1. Master List and other platforms for exchange
The Master List (spreadsheet) has been the central tool of the programme
since its inception. It serves as the primary mechanism for communication
and information sharing among participating authorities and supports
inspection planning and decision-making.
The Master List
• Includes API manufacturing sites of interest to participating authorities,
located outside their jurisdictions
• Captures key information on the inspection history and planned
inspections across authorities.
Historically, the Master List was periodically published in the protected
module of EudraGMDP for reference by participants and maintained by the
acting secretariat based on information provided by the authorities. In
addition, some authorities recorded inspection data in the EudraGMDP
planning module
During the 2017-2024 period, the Master List was no longer uploaded to
EudraGMDP. However, it was further developed and enriched to improve
monitoring and coordination, including:
• Site identification codes (e.g. USFDA FEI, ANVISA id, TGA id, DUNS,
SPOR LOC id, GEO),
• Additional data field to support monitoring of key performance
indicators (KPIs), such as duplication, reliance, specific risks (e.g.
nitrosamines), and sites of common interest
In addition to the Master List, inspection-related information is also
accessible through specific authority systems, such as Eudra GMDP (EU), the
COMSTAT/FACTS platform (US FDA), and WHOPIRS (WHO), which
complement the programme’s internal information exchange mechanisms.
5.2. Non-compliance Alerting and Regulatory action
The programme includes mechanisms for the early exchange on sites
identified as being non-compliant with GMP.
Within the scope of existing confidentiality agreements, some of the
participating authorities regularly exchanged information on GMP non-
compliant sites prior to such information being made publicly available by the
EMA/202541/2026 Page 5/17
第 6 页
relevant authority (e.g. through Warning Letters or draft Statements of GMP
Non-Compliance).
Future inspection plans related to GMP non-compliance have also been
shared and, where deemed necessary, other participating authorities may
follow up by proposing a joint re-inspection.
In addition to inspection outcomes, some participating authorities have also
shared early notification of regulatory actions, including license suspensions
and other national enforcement measures taken against non-compliant
manufacturers.
5.3. Secretariat of the group, monthly meetings, bi/multilateral
meetings
The authority/agency responsible for the secretariat organizes the monthly
teleconferences and manages key documentation, including meeting minutes
and Master List. These teleconferences are intended to facilitate the
exchange of information on upcoming inspections, inspection outcomes and,
where applicable, the follow-up of inspections performed. The information
shared during these teleconferences forms the basis for subsequent bi-or
multilateral exchange of documents and/or the organization of joint
inspections.
After a prolonged period during which EMA and USFDA jointly held the
secretariat, a rotation system has been introduced to prevent the
concentration of secretariat responsibilities on a limited number of authorities
and to distribute the workload more evenly, as shown in Table 1 below.
Table 1: The rotation schedule for the secretariat function of the API
Programme from 2008 – 2024, including which participating authority was
secretariat during each rotation.
Time Period API Programme
Secretariat
Until January 2020 USFDA-EMA
January 2020 – March 2020 HC
April 2020 – September 2020 EMA
October 2020 – March 2021 WHO
April 2021 – October 2021 ANSM
November 2021 – April 2022 PMDA
May 2022 – October 2022 DKMA
November 2022 – April 2023 HPRA
May 2023 – December 2024 EDQM
EMA/202541/2026 Page 6/17
第 7 页
In addition to the monthly meetings, numerous bilateral or multilateral
exchanges took place to address specific needs such as cross-checking
information, exchanging reports, planning joint inspections, and coordinating
reliance activities.
Participation in the monthly meetings varied due to resource constraints,
staff turnover, and evolving priorities among the participating authorities.
6. Deliverables
For the period 2017-2024, the Master List served as the primary source for
compiling the various deliverables, as it is the main document used for
information sharing within the group.
Deliverables are presented and assessed in a manner consistent with the
previous report.
To the extent possible, data from the reviewed period are presented
alongside data from the previous period.
In the data presented below, the term “Europe” refers to sites and
inspections associated with EDQM’s Certification of Suitability (CEP) scheme,
inspections requested in the context of centrally authorised products in EU
(EMA/European Commission), EU inspectorates participating in this
programme, and the MHRA.
6.1. Number of sites inspected and number of inspections
Based on the Master List, the number and distribution of inspected sites and
inspections, regardless shared interest or not are presented as follows:
Table 2: A comparison of the total number of sites and number of inspections
(total and per authority) between the 2011 – 2016 time period, and 2017 –
2024 time period.
2011-2016 2017-2024
10 authorities 13 authorities
Total sites 944 936
Total inspections 1333 1684
Inspections, by
authority
“Europe” * 310 275
ANVISA - 129
USFDA 762 686
EMA/202541/2026 Page 7/17
第 8 页
HC-SC - 63
PMDA - 292
TGA 130 136
WHO 131 103
* “Europe” includes ANSM, EDQM, DKMA, HPRA, MHRA, AIFA, and
EMA
• The number of participating authorities increased from 10 to 13.
• The overall number of sites inspected remained broadly stable over the
period.
• The total number of inspections increased by approximately 50%
6.2. Sites of shared interest
There have been 644 sites of shared interest out of 936, distributed as
shown below in Figures 1 & 2.
Figure 1: Geographical distribution of sites of common interest. The 644 sites
of common interest were in 18 countries: 35% in China and 50% in India,
14% in the remaining 16 countries (“ROW”, 14%).
Geographic distribution of sites
450 India
400 China
350 India
300
250 China
200 ROW
150
ROW
100
50
0
Sites total Sites of common interest
EMA/202541/2026 Page 8/17
第 9 页
Figure 2: Number of sites that have been of shared interest between two or
more authorities between 2017 and 2024. Out of 936 unique sites handled
during the period, 644 (69%) were of shared interest to at least 2
authorities. The remaining 292 (31%) sites were of shared interest to 3 to 7
authorities.
Number of authorities interested by the same site
350
292
300 261
250 207
200
150 113
100
44
50 19
0
Interest of 1 Interest of 2 Interest of 3 Interest of 4 Interest of 5 Interest of 6-7
6.3. Multiple (duplicates) inspections
For the purposes of the API Programme, a duplicate inspection is defined as
an inspection of the same site conducted by two or more authorities within
12-month timeframe. Overall, 32% of the sites were subject to duplicate
inspections during the period.
To enhance the level of detail, this report incorporates two duplication
intervals:
• Less than 6 months: 147 (23% of the inspections)
• Between 6 and 12 months: 57 (9% of the inspections)
Figure 3: Number of sites impacted by duplication of inspections.
Sites impacted by duplications
Duplication < 6
months, 147, 23%
No
Duplication 7-12
duplication,
months, 57, 9%
440, 68%
EMA/202541/2026 Page 9/17
第 10 页
Comments:
• A single duplication may correspond to two or more inspections.
• Multiple duplications may occur at the same site
• A correction factor of 50% was applied as some sites were affected by
both duplication intervals (“less than 6 months” and “6 -12 months”)
In addition, as sites with non-compliant outcomes often trigger additional
inspections or re-inspections, these data were considered together in the
analysis.
Table 3: Average number of duplicate inspections per site by participating
authorities from 2011 - 2016.
Duplicate inspections Average nb of
Nb
(2011-2016) and Nb of inspections per
of
correlation with inspections site by 10
sites
inspection outcome authorities
46 107 2.3
Sites with more than one
non-compliant outcome
Compliant sites 205 358 1.7
Table 4: Average number of duplicate inspections per site by participating
authorities from 2017 – 2024.
Duplicate inspections Average nb of
(2017-2024) and Nb
Nb of inspections per
correlation with of
inspections site by 13
inspection outcome sites
authorities
49 156 3.1
Sites with more than one
non-compliant outcome
Compliant sites 155 353 2.3
Figure 3 and Tables 3 & 4 show that:
• The majority of duplicate inspections occurred within a period of less
than 6 months;
• Sites that received a non-compliant outcome from one authority were
more likely to trigger additional inspections by other authorities
compared to compliant sites. During the period 2011–2016, such sites
EMA/202541/2026 Page 10/17
第 11 页
underwent approximately 33% more inspections than compliant sites;
this difference increased to 49% in the period 2017–2024. One
contributing factor may be the increase in the number of authorities
from 10 to 13. As a result, the number of sites of shared interest
increased from 458 to 644, significantly raising the likelihood of
duplicate inspections. This increase should therefore be interpreted in
the context of the growing number of authorities;
• In parallel the number of compliant sites affected by duplicate
inspections decreased approximatively by 25% compared to the
previous period (2011-2016).
Other factors that may explain the duplicate inspections were already
identified in the previous report, and remain valid:
• The scope of inspections may differ significantly. For example,
inspection may be limited to a specific API within a preapproval
process, or the type of API may vary substantially;
• New information may trigger an inspection, even if a recent inspection
has already taken place;
• The Master List may not always contain timely and complete
information on inspections, leading to scheduling conflicts that cannot
be resolved due to limited time or internal, logistical, administrative, or
legal constraints;
• Short notice inspections, particularly those with limited prior
notification to companies, may prevent coordination or optimisation of
inspection planning.
6.4. Remote inspections
Remote inspections/assessments did not exist during the previous period;
they have been implemented by some members as a response to the
lockdown situation caused by the COVID-19 pandemic. 91 remote
inspections were carried out (5%), mainly during the last years of the 2017-
2024 period.
Continuing to use remote inspections/assessments can contribute to smarter
use of resources and stronger environmental protection. However, the scope
of remote inspections/assessments remains limited: they cannot fully
substitute for on-site inspections, and some members have legal
requirements to mandate on-site inspections.
In that sense, the ICMRA Collaborative Hybrid Inspection Pilot, which
foresees a combination of on-site and remote inspections/assessments of
finished products manufacturers, may represent a promising approach.
EMA/202541/2026 Page 11/17
第 12 页
6.5. Joint inspections
Joint inspections have been one of the tools for work sharing since the
beginning of the programme, fostering a high level of trust among
participating authorities. The practice was continued occasionally during the
2017-2024 reporting period as a means of continuing to enrich that
confidence. While in the first years a reporting form was setup to routinely
capture inspectors’ feedback for each such inspection, this practice has been
discontinued.
Participants acknowledged that joint inspections required significantly more
planning and resources than simply sharing inspection information. They
require an additional level of communication to coordinate the background
information, financial arrangements and logistics within and across the
inspection teams, as well as site-level adjustments to accommodate
inspectors from more than one region working together. On the other hand,
their benefit is to create more opportunities to exchange information among
inspectors and their managers potentially allowing for more harmonised
approaches and more reliance and trust.
In total 27 joint inspections were conducted at 25 sites, representing 4.2% of
the 644 sites of shared interest.
By comparison, in the previous six-year period, 47 joint inspections were
performed at 43 sites, accounting for 10% of 458 sites of shared interest.
The decline in joint inspections potentially reflects the growing efficiency of
information-sharing and reliance practices. This optimizes resources but also
strengthens strategic collaboration by reducing redundant efforts.
6.6. Sharing reports and using reliance for the supervision of sites
The group has implemented other mechanisms to recognize or acknowledge
inspections conducted by another region for sites of common interest among
different authorities. This approach of inspection reliance is defined in WHO’s
Good Reliance Practices (TRS 1033, Annex 10) and PIC/S Guidance PI 048-1.
Inspection reliance was reported on 107 sites out of 644 (17%), most of
them strictly corresponding to the definition of inspection reliance. For
example, reviewing GMP certificates or equivalent deliverables, reviewing
inspection reports from other authorities, provided either by the companies
or by the authorities. For a number of cases, inspections were postponed
after getting the knowledge that another authority had planned the
inspection.
EMA/202541/2026 Page 12/17
第 13 页
Figure 4: The number of sites with reported inspection reliance, where the
review of GMP certificates, reports and/or supporting documents was done in
lieu of an inspection.
Reliance
Sites were
reliance was
reported,
107, 17%
Other sites of
Common interest
where no reliance
was reported,
537, 83%
The numbers presented in Figure 4 may be underestimated as the group
has not discussed beforehand the opportunity to specifically track how
often a decision was taken to not inspect, or to postpone inspection for a
site that otherwise would have been inspected. Therefore, the practice of
each participant may have varied over the review period of this report. For
example, inspection reliance may have been reported during the COVID
lockdown period and discontinued once the onsite inspections resumed,
mainly to manage overall workload.
Sharing reports was noted by participants as a key of the programme, often
prompting clarifying conversations during monthly teleconferences.
Challenges encountered in sharing or using reports are:
• The language in which the reports are written and the fact that it is not
possible to use online translation tools, due to data confidentiality
requirements.
• The necessity to obtain permission from the manufacturer before
sharing the report
• The necessity to have specific sections anonymized and/or redacted to
comply with local legal requirements. This process is often time-
consuming, which delays or even compromise their availability. As an
alternative, in some situations, reports can be requested directly from
the inspected manufacturing sites.
Overall, inspection reliance was applied to 107 sites, mainly through
reviewing GMP certificates or reports and occasionally postponing
inspections. Figures are likely underestimated due to inconsistent tracking
EMA/202541/2026 Page 13/17
第 14 页
and varied practices, especially during COVID. Key challenges include
language barriers, confidentiality requirements, and delays in report sharing.
Exchanging reports also helps prepare inspections and follow up on major
GMP issues.
6.7. Sustained engagement of participating authorities
A questionnaire was developed and circulated amongst the participants
between March and May 2024. The objective was to assess the level of
commitment of the responders to meet the goals of the International API
programme.
Most of the participating authorities showed a generally positive
commitment, provided that internal resources and legal provisions allow it.
The strongest ability to commit was observed in sharing planned
inspections and outcomes. Practical implementation of other goals such as
sharing inspection reports, inspection reliance, and requesting scope
expansion, indicated moderate progress with room for improvement. Joint
inspections remain the most challenging area, which is confirmed by the
50% decrease compared to the previous period.
Overall, the survey confirmed the sustained engagement of the members
and that close information exchange within authorities is the key to
success. Therefore, the importance to make improvements centred on
increasing the efficiency of information sharing.
7. Achievement of the recommendations from the previous report
Recommendations from the previous reports were not or partially addressed
within the period covered by the present report. These recommendations
were to develop and implement:
• A shared database with a comprehensive list of API manufacturers
registered in the different participants’ countries
o The master list fulfils the needs and has been improved
throughout times
o However, a common share point / host for the Master List with
simultaneous access by group members has not been
established
• A common policy framework related to the re-inspection of shared
sites located in third countries
o The existing provisions were considered sufficient
• A formal, central repository with write access hosting the Master
List, inspection reports, etc.
o While the principle was agreed by all members, the choice
EMA/202541/2026 Page 14/17
第 15 页
of a technical solution that meets the security
requirements and legal constraints of all authorities could
not be identified
• Amplify the usage of the EudraGMDP planning module by all EEA
members and API Programme participants
o Not in place for several members, for technical reasons or
resources constraints (need to record in duplicate in
EUDRA and in the Master List)
• Guidelines and further remote training sessions amongst
participants on how to prepare, conduct and follow-up on joint
inspections
o No specific guideline as one already exists at PIC/S level
• Encourage participants to the API Programme to a more active
participation and input during the teleconferences.
o Improved, still an ongoing process
8. Recommendations for future action and path forward
The review confirms that the International API Inspection Programme
remains a cornerstone for global GMP oversight of API manufacturers.
While progress has been made in expanding membership, increasing
information sharing, inspection reliance and inspections, introducing
remote tools, several recommendations from previous reports remain
valid.
Moving forward, priorities include:
I. Regular participation and information sharing
1. Attend teleconferences regularly and contribute actively during the
discussions by sharing all relevant information in due time
II. Better sharing and planning tools
2. Continue improving the Master List to enable better visibility and
quantification of duplicated inspection
3. Discuss the relevance to use of the EudraGMDP planning module by all
EU/EEA members and API Programme participants
4. Discuss the relevance to resume uploading the Master List regularly in
the protected module of EudraGMDP.
EMA/202541/2026 Page 15/17
第 16 页
III. Tools and practices for reliance
5. Discuss the relevance to pursue efforts in seeking a technical solution
that meets the security requirements and legal constraints of all
authorities for a formal, central repository with write access for hosting
the Master List, inspection reports etc.
6. Improve inspection reports usability by providing at least a summary in
English, together with detailed scope and extent of the inspection to
foster reliance
7. Discuss the relevance to share information on inspection reliance within
the group and its adequate frequency
8. Discuss the relevance to promote joint inspections, including by hybrid
inspections combining on-site and remote inspections
9. From a broader perspective, consider addressing legal and resource
hurdles which jeopardize commitments taken within this group.
IV. Decrease duplicated inspections
10. Record and discuss the root causes for duplication
11. Discuss an action plan which includes I, II and III above.
V. Workload for running the API programme
12. Recommend sharing the workload and responsibilities of the
secretariat into 2 authorities to ensure continuity and efficiency
(implemented mid-2025).
13. Recommend sharing the workload and responsibilities for the
preparation of the activity report into several authorities, discuss how to
make it easier, more straightforward, and discuss the optimal period.
9. Conclusion
In conclusion, efforts to reduce duplicate inspections have been effective
within a number of authorities. However, it highlights the importance to
share timely information on planned inspections with the group, to replan
the work accordingly, if possible and in line with the objective of the
planned inspections. This objective has become both more important and
more challenging due to the growing number of authorities within the
group.
EMA/202541/2026 Page 16/17
第 17 页
The benefits of continuing information sharing on planned inspections and
reducing duplicate inspections are substantial:
• More strategic allocation of inspection resources,
• Reduced burden for all stakeholders, manufacturing sites and national
inspectorates,
• Better preservation of the environment.
With sustained commitment, active participation, deeper collaboration, and
enhanced information sharing, including technological and legal
advancements, the programme can better cope with increasing complexity,
strengthen international cooperation and reliance, optimize inspection
resources, and uphold the integrity of the global pharmaceutical supply
chain.
10. References
API Pilot final report 2011-2016:
https://www.ema.europa.eu/en/documents/report/report-international-
active-pharmaceutical-ingredient-inspection-programme-2011-2016 en.pdf
API Programme Terms of Reference:
https://www.ema.europa.eu/en/documents/other/pilot-programme-
international-cooperation-gmp-inspection-manufacturers-sterile-medicinal-
products-human-use-terms-reference-participating-authorities en.pdf
WHO’s Good Reliance Practices: TRS 1033, Annex 10
https://www.who.int/publications/m/item/annex-10-trs-1033
PIC/S Guidance PI 048-1:
https://picscheme.org/docview/2475
ICMRA Pilot Programme for Collaborative Hybrid Inspection
https://www.icmra.info/drupal/sites/default/files/2022-
06/overall plan for collaborative hybrid inspection.pdf
EMA/202541/2026 Page 17/17
来源:EMA 官方医药监管信息 · ema.europa.eu